Values of CI (0.57, 0.814 and 0.507 for A375, SK-MEL-28 and RPMI-7951 respectively for combination of 20μM fisetin and 5μM sorafenib; and 0.44, 0.774 and 0.513 for A375, SK-MEL-28 and RPMI-7951 respectively for combination of 20μM fisetin and 10μM sorafenib) clearly demonstrated that combination treatment exerted synergistic growth inhibition of BRAF-mutated melanoma cells (Table 1). This evidence concerns the gene BRAF and melanoma.